Elanco produces drugs and vaccines for pets and livestock. The purchase is expected to close by mid-2019. Based on the exchange ratio and the closing prices on April 24, 2019, Aratana's stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. Our worldwide headquarters and research facilities are located in Greenfield, Indiana. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. Terms were not announced. LEAWOOD, Kan. (U.S.) (For EU audience), November 10, 2017 — Elanco Animal Health, a division of Eli Lilly and Company (NYSE: LLY) and Aratana Therapeutics, Inc. … Besides Galliprant, described as a first-of-its-kind NSAID for canine osteoarthritis, Aratana makes: Among products under development are a canine osteosarcoma vaccine, an anti-viral treatment for feline herpes virus-induced ophthalmic conditions and an oral antagonist for the prevention of clinical signs of atopic dermatitis in at-risk dogs. The Greenfield, Indiana, company expects 2019 revenue of more than $3.1 billion. Elanco Finalizes Acquisition of Aratana Therapeutics, https://www.businesswire.com/news/home/20190718005410/en/. For further discussion of these and other risks and uncertainties, see Elanco’s most recent filings with the United States Securities and Exchange Commission. The Leawood, Kansas, company in March reported a 2018 net loss of $14.7 million against net revenue of $35.4 million. Elanco, Aratana Announce Positive Opinion on GALLIPRANT® (grapiprant tablets) in Europe. Close. Investor Relations: Jim Greffet (317) 383-9935 or [email protected], Source: Elanco Animal Health Incorporated. The closing of the merger will take place no later than two business days following when the last of the closing conditions of the merger have been satisfied or waived. Written by Today's Veterinary Business in April 2019. View source version on businesswire.com: Elanco now anticipates closing the deal Aug. 3. Based on the exchange ratio and the closing prices on April 24, 2019, Aratana’s stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. Jeff Simmons, Elanco’s president and CEO, called Aratana “one of the most innovative start-ups in animal health.”. Aratana’s president and CEO, Craig Tooman, pointed his company’s “strong track record as a drug developer” and to “our field team’s unmatched expertise delivering innovation to veterinary specialists.”. https://www.businesswire.com/news/home/20190718005410/en/, Media: Colleen Parr Dekker at (317) 989-7011 or [email protected] Web Design by PHOS Creative, Elanco Obtains Rights to KindredBio Parvovirus Therapy, Laser therapy provider LiteCure gets new owner. Based on the exchange ratio and the closing prices on April 24, 2019, Aratana's stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana … The purchase is expected to close by mid-2019. “Aratana’s strong position in the specialty market – with their current portfolio and pipeline – complements Elanco’s field presence and capitalizes on new opportunities for key existing Elanco pet therapy brands,” said Jeff Simmons, president and chief executive officer of Elanco. Additionally, Aratana contributes two additional products to Elanco’s portfolio: Entyce®, the only FDA-approved veterinary therapeutic to stimulate appetite in dogs, and Nocita®, a long-acting local anesthetic that provides up to 72 hours of post-operative pain relief following certain surgeries in dogs and cats. The deal is structured as a stock-for-stock transaction. Last year, Elanco bought Leawood-based Aratana Therapeutics Inc. for $245 million and has incorporated Aratana’s sales force to serve the specialty vet clinic market. Elanco Animal Health Inc (NYSE: ELAN) announced Friday that it has struck a deal to buy pet therapeutics company Aratana Therapeutics Inc (NASDAQ: PETX). We value innovation, both in scientific research and daily operations, and strive to cultivate a collaborative work environment for more than 5,800 employees worldwide. Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant ® . Elanco has also begun the formation of a new commercial team dedicated to the veterinary specialty business into which the Aratana field force will transition. Subject to the terms of the agreement, upon the closing of the transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. Elanco Animal Health has agreed to purchase Aratana Therapeutics, developer of the canine osteoarthritis drug Galliprant, in a stock transaction valued at $245 million. News zur ELANCO ANIMAL HEALTH AKTIE und aktueller Realtime-Aktienkurs Fitch Ratings downgrades LT Int. Elanco in 2016 acquired the exclusive rights to manufacture and commercialize Galliprant (grapiprant tablets). Elanco in 2016 acquired the exclusive rights to manufacture and commercialize Galliprant (grapiprant tablets). Based on the exchange ratio and the closing prices on April 24, 2019, Aratana’s stockholders would receive Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. Statements in this document that are not strictly historical, including statements regarding benefits of the acquisition of Aratana, future opportunities for the combined businesses and any other statements regarding events or developments that we believe or anticipate will or may occur in the future, may be “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. – Elanco shares issuable constitute ~2% of Elanco shares outstanding – Aratana shareholders receive 0.1481 Elanco shares and contingent value rights of $0.25 per Aratana share if certain milestones are met – Stock portion of the deal is valued at $4.75, a ~40% premium to Aratana closing price on 4/24/19* – Terms not disclosed Between March 24, 2019, and April 25, 2019, Elanco and Aratana reached a deal elevating the implied value of Aratana stock from $4.15 to $4.75. On April 26, 2019, Aratana signed an agreement to be acquired by Elanco Animal Health in a stock-for-stock transaction. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support In 2016, Elanco paid Aratana $45 million for the rights to sell that drug outside of the US, and for the right to co-promote it within the US. In announcing the acquisition of Aratana, Elanco also reported signing a development and commercialization agreement with VetDC for Tanovea-CA1, a conditionally approved canine lymphoma treatment. Get the latest business resources on the market delivered to your inbox. Read More. This stock portion of the deal Based on the exchange ratio and the closing prices from April 24, 2019, Aratana’s shareholders would receive the number of Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. Elanco Selects Indiana as Home for Global HQ and Future Footprint Consolidation . The purchase is expected to close midyear and is subject to customary closing conditions, including approval by Aratana shareholders and antitrust clearance, Elanco … This website uses cookies and other technologies to function correctly, analyze site usage, and allow us and the advertising partners we work with to provide you with advertisements based on your interests. Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant®. “As a newly independent, premier animal health company, we believe that Elanco would help expand our portfolio with their substantial resources and presence within the companion animal segment,” Tooman said. This specialty sales force makes Elanco unique – with a focus on serving an important and growing segment in veterinary care, and offering tailored products for the most complex and specialized approaches in veterinary medicine, like surgeries and oncology. The CVR of $0.25 per Aratana share will be paid in cash if capromorelin … Aratana’s research and development pipeline will also contribute to Elanco’s efforts to sustain the introduction of novel and innovative companion animal therapeutics. At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. Founded in 1954, Elanco provides comprehensive products and knowledge services to improve animal health and food-animal production in more than 90 countries around the world. Elanco, the world’s fourth-largest animal health company, was an early backer of 9-year-old Aratana as the smaller firm ramped up its research and product pipeline. These factors include risks and uncertainties related to, among other things, the possibility that the integration of Aratana’s business and operations with those of Elanco may be more difficult and/or take longer than anticipated, may be more costly than anticipated and may have unanticipated adverse results relating to Aratana’s or Elanco’s existing businesses, and other factors that may affect future results of the combined company described in the section entitled “Risk Factors” in the proxy statement/prospectus mailed to Aratana’s stockholders in connection with the transaction. Elanco Animal Health (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. The company put out the date in a Monday release in which it announced that the European Commission approved the … Elanco Animal Health (NYSE:ELAN) today announced it has signed an agreement to acquire Aratana Therapeutics (NASDAQ:PETX), a pet therapeutics company focused on developing and commercializing innovative therapeutics for dogs and cats, and developer of the first-of-its-kind canine NSAID for osteoarthritis, Galliprant. Elanco Animal Health Incorporated (NYSE: ELAN), today finalized the acquisition of Aratana Therapeutics (NASDAQ: PETX), a pet therapeutics company foc Elanco announced Indiana as its base for future global consolidated operations, anchored by a new streamlined fit-for-purpose global headquarters in downtown Indianapolis. Except as required by law, Elanco undertakes no duty to update forward-looking statements to reflect events after the date of this release. Copyright © 2020 Today's Veterinary Business. Subject to the terms of the agreement, upon the closing of the transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. Download PDF Media Contacts Karin Gerbens [email protected] +32 476 978 467. Together with our customers, we are committed to raising awareness about global food security, and celebrating and supporting the human-animal bond. Elanco, the world’s fourth-largest animal health company, was an early backer of 9-year-old Aratana as the smaller firm ramped up its research and product pipeline. This transaction allows Elanco to capture the full value of growing product Galliprant®, in which Elanco has had the exclusive rights to develop, manufacture and commercialize since 2016. Elanco says the deal would allow it to integrate the Aratana portfolio of pet therapeutics into its companion animal therapeutics business. Elanco has also signed a development and commercialization agreement … Learn why we're a leading provider of innovative solutions that protect and enhance animal health. Scale (foreign curr.) Aratana … Aratana has slowly generated revenue but has yet to turn a profit. Rachel Reiff [email protected] +1 (913) 353-1050. Living Our Healthy Purpose. “This deal furthers Elanco’s value-generating IPP strategy (Innovation, Portfolio and Productivity) while continuing to bring great value to veterinarians and pet owners.”. “We believe the deal would bring greater value to veterinarians and pet owners, as well as both Elanco and Aratana shareholders,” Simmons said. the closing prices from April 24, 2019, Aratana’s shareholders would receive the number of Elanco shares equivalent to an implied value of $4.75 per Aratana share, representing a premium of approximately 40 percent, plus one CVR per Aratana share. GREENFIELD, Ind.--(BUSINESS WIRE)-- Elanco Animal Health Incorporated (NYSE: ELAN) today announced that is has priced its previously announced concurrent public offerings of 22,694,732 shares of its common stock at $32.00 per share and 11,000,000 of its 5.00% tangible equity units, with a stated amount of $50 per unit. credit rating of Elanco Animal Health to BB; outlook stable Elanco Animal Health Incorporated today announced the closing of its previously announced initial public offering (“IPO”) of 62.9 million shares of its common stock at a price to the public of $24.00 per share. VetDC is a start-up company spun off from Colorado State University. At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana … At the close of the stock-for-stock transaction, Aratana stockholders will receive 0.1481 share of Elanco common stock and one contingent value right (CVR) for each share of Aratana common stock. Nocita (bupivacaine liposome injectable suspension), a local anesthetic formulated to provide up to 72 hours of post-operative pain relief in dogs and cats.